LCS
HBIO icon

Levin Capital Strategies’s Harvard Bioscience HBIO Stock Holding History

Levin Capital Strategies’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-21,660
Closed -$864K – 327
2013
Q3 		$864K Buy
+21,660
New +$852K 0.01% 217

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCAM
F&C Asset Management Edinburgh, Scotland, United Kingdom $7.92B AUM 24.35% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PM
Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Levin Capital Strategies's HBIO Position: Q4 2013 in Review

Levin Capital Strategies sold out of Harvard Bioscience (HBIO) in Q4 2013, closing a stake of 21,660 shares — an estimated $864K sold.

Levin Capital Strategies first reported a position in HBIO in Q3 2013 and held it in 1 quarter. The position peaked at $864K in Q3 2013. 77 funds tracked by Wall St. Rank hold HBIO as of Q4 2013.

  • Levin Capital Strategies reported no remaining Harvard Bioscience position as of Q4 2013 after selling out during the quarter.
  • Levin Capital Strategies sold 21,660 Harvard Bioscience shares in Q4 2013, an estimated $864K.
  • Levin Capital Strategies first reported a position in Harvard Bioscience in Q3 2013 and held it in 1 quarter.
  • Levin Capital Strategies's Harvard Bioscience position peaked at $864K in Q3 2013.
  • 77 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2013.

Based on Levin Capital Strategies's 13F filing for Q4 2013, filed 13 Feb 2014.